Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event

Acta Neurologica Scandinavica

Volumn 115, Issue 6, 2007, Pages 429-431

  Pakdaman, H ^a   Sahraian, M A ^b   Fallah, A ^a   Pakdaman, R ^b   Ghareghozli, K ^a   Ghafarpour, M ^b   Rahimian, E ^a   Shirani, A ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinically isolated syndrome; Interferon beta 1a; Interferon treatment; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; PLACEBO;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOTHERAPY; IRAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; BRAIN; DEMYELINATING DISEASES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; IRAN; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 34248673155     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00813.x     Document Type: Review

References (15)

1. Dalton CM, Brex PA, Miszkiel KA et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002 52: 47 53.
2. Filippi M, Horsfield MA, Morrissey SP et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994 44: 635 41.
3. PRISMS (Prevention of Relapses and Disability by Interferon Beta 1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon Beta-la in relapsing/remitting multiple sclerosis. Lancet 1998 352: 1498 504.
4. Lublin F. History of modern multiple sclerosis therapy. J Neurol 2005 252 (Suppl. 3 iii3 9.
5. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997 120: 393 9.
6. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001 14: 271 8.
7. De Stefano N, Narayanan S, Francis GS et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001 58: 65 70.
8. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 343: 898 904.
9. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001 357: 1576 82.
10. Sriram U, Barcellos LF, Villoslada P et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 2003 4: 147 52.
11. Sturzebecher S, Wandinger KP, Rosenwald A et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 1419 126: 1419 29.
12. Polman CH, Kappos L, Freedman MS et al. Betaferon® in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): subgroup analyses. Paper presented at the 16th Meeting of the European Neurological Society, Lausanne, Switzerland, 2006 27 31.
13. The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon beta-1a dose response in relapsing-remitting MS. Neurology 1999 53: 679 86.
14. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 352: 1498 504.
15. Langer-Gould A, Popat RA, Huang SM et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006 63: 1686 91.